Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase.
CYP450 inductors
antiseizure medications
drug-drug interactions
gabapentinoids
pharmaco-epidemiology
road traffic accidents
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
08
07
2022
received:
07
02
2022
accepted:
01
08
2022
pubmed:
9
8
2022
medline:
22
12
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Due to their central mechanism of action, antiseizure medications (ASMs) could lead to adverse effects likely to impair driving skills. Their extended use to neuropsychiatric disorders makes it a class of drugs to monitor for their road traffic accidental (RTA) potential. We aimed to assess the reporting association between ASMs and RTAs using the World Health Organization pharmacovigilance database (VigiBase). We performed a disproportionality analysis to compute adjusted reporting odds ratios to evaluate the strength of reporting association between ASMs and RTAs. A univariate analysis using the reporting odds-ratio was used to assess drug-drug interactions between ASMs and RTAs. There were 1 341 509 reports associated with at least 1 ASM in VigiBase of whom 2.91‰ were RTAs reports. Eight ASMs were associated with higher reporting of RTAs compared to others (ranging from 1.35 [95% confidence interval 1.11-1.64] for lamotrigine to 4.36 [95% confidence interval 3.56-5.32] for cannabis). Eight significant drug-drug interactions were found between ASMs and the onset of RTA, mainly involving CYP450 induction. A significant safety signal between RTAs and some ASMs was identified. Association of several ASMs might further increase the occurrence of RTA. ASMs prescription in patients with identified risk factors of RTA should be considered with caution. Study number: ClinicalTrials.gov, NCT04480996.
Banques de données
ClinicalTrials.gov
['NCT04480996']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-231Informations de copyright
© 2022 British Pharmacological Society.
Références
Sirven JI, Noe K, Hoerth M, Drazkowski J. Antiepileptic Drugs 2012: Recent Advances and Trends. Mayo Clin Proc. 2012;87(9):879-889. doi:10.1016/j.mayocp.2012.05.019
Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6(2):57-75.
Devlin AL, Odell M, Charlton LJ, et al. Epilepsy and driving: Current status of research. Epilepsy Res. 2012;102(3):135-152. doi:10.1016/j.eplepsyres.2012.08.003
Orriols L, Foubert-Samier A, Gadegbeku B, et al. Prescription of antiepileptics and the risk of road traffic crash. J Clin Pharmacol. 2013;53(3):339-344. doi:10.1002/jcph.10
Andrew T, Milinis K, Baker G, Wieshmann U. Self reported adverse effects of mono and polytherapy for epilepsy. Seizure. 2012;21(8):610-613. doi:10.1016/j.seizure.2012.06.013
Witt J-A, Elger CE, Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: Each additional drug matters. Eur Neuropsychopharmacol. 2015;25(11):1954-1959. doi:10.1016/j.euroneuro.2015.07.027
Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord. 2004;6(3):153-168.
Sundelin HEK, Chang Z, Larsson H, et al. Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study. Neurology. 2018;90(13):e1111-e1118. doi:10.1212/WNL.0000000000005210
Brubacher JR, Chan H, Erdelyi S, Zed PJ, Staples JA, Etminan M. Medications and risk of motor vehicle collision responsibility in British Columbia, Canada: a population-based case-control study. Lancet Public Health. 2021;6(6):e374-e385. doi:10.1016/S2468-2667(21)00027-X
Orriols L, Salmi L-R, Philip P, et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf. 2009;18(8):647-658. doi:10.1002/pds.1763
Orriols L, Luxcey A, Contrand B, et al. Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study. Br J Clin Pharmacol. 2016;82(6):1625-1635. doi:10.1111/bcp.13075
Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol. 2008;22(2):127-140. doi:10.1111/j.1472-8206.2007.00552.x
Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase®. Psychol Med. 2020;51(9):1-8. doi:10.1017/S0033291720000161
Delafoy C, Dolladille C, Besnier P, et al. Clinically significant drug-drug interactions between tramadol and CYP3A4 inhibitors: disproportionality analysis in VigiBase® and hypothesis on the underlying mechanism. Eur J Clin Pharmacol. 2020;76(7):1049-1051. doi:10.1007/s00228-020-02881-5
Fernandez S, Lenoir C, Samer CF, Rollason V. Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. J Pers Med. 2021;11(4):250. doi:10.3390/jpm11040250
Faillie J-L. Case-non-case studies: Principle, methods, bias and interpretation. Therapie. 2019;74(2):225-232. doi:10.1016/j.therap.2019.01.006
Chavant F, Favrelière S, Lafay-Chebassier C, Plazanet C, Pérault-Pochat MC. Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2011;72(6):898-904. doi:10.1111/j.1365-2125.2011.04009.x
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905-908. doi:10.1111/j.1365-2125.2011.04037.x
Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483-486. doi:10.1002/pds.677
Noguchi Y, Yoshizawa S, Aoyama K, Kubo S, Tachi T, Teramachi H. Verification of the “Upward Variation in the Reporting Odds Ratio Scores” to Detect the Signals of Drug-Drug Interactions. Pharmaceutics. 2021;13(10):1531. doi:10.3390/pharmaceutics13101531
Li G, Chihuri S. Prescription opioids, alcohol and fatal motor vehicle crashes: a population-based case-control study. Inj Epidemiol [Internet] 2019 [cited 2020 Apr 29];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582661/
Bauer J, Cooper-Mahkorn D. Tiagabine: efficacy and safety in partial seizures - current status. Neuropsychiatr Dis Treat. 2008;4(4):731-736. doi:10.2147/NDT.S833
Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104-114. doi:10.1177/2049463720912496
Drummer OH. Benzodiazepines - Effects on Human Performance and Behavior. Forensic Sci Rev. 2002;14(1-2):1-14.
Gordon AM, Logan BK. Topiramate-Positive Death-Investigation and Impaired-Driving Cases in Washington State. J Anal Toxicol. 2006;30(8):599-602. doi:10.1093/jat/30.8.599
Sommer BR, Mitchell EL, Wroolie TE. Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord. 2013;6(4):211-227. doi:10.1177/1756285613481257
Verster JC, Roth T. Gender Differences in Highway Driving Performance After Administration of Sleep Medication: A Review of the Literature. Traffic Inj Prev. 2012;13(3):286-292. doi:10.1080/15389588.2011.652751
Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. Different aspects of driving under the influence of benzodiazepines. Med Sci Law. 2016;56(2):159-160. doi:10.1177/0025802415594832
Dokkedal-Silva V, Berro LF, Galduróz JCF, et al. Clonazepam: Indications, Side Effects, and Potential for Nonmedical Use. Harv Rev Psychiatry. 2019;27(5):279-289. doi:10.1097/HRP.0000000000000227
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy Curr. 2018;18(4):269-278. doi:10.5698/1535-7597.18.4.269
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Epilepsy Curr. 2018;18(4):260-268. doi:10.5698/1535-7597.18.4.260
Molero Y, Larsson H, D'Onofrio BM, et al. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:l2147. doi:10.1136/bmj.l2147
FDA Drug Safety Communications. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin. Lyrica: Lyrica CR; 2019:1-9.
Shen Y, Zhang M, Wang Y, et al. Subjective sleep disturbance in Chinese adults with epilepsy: Associations with affective symptoms. Epilepsy Res. 2017;135:150-157. doi:10.1016/j.eplepsyres.2017.06.014
Brodie MJ, Ben-Menachem E, Chouette I, Giorgi L. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand. 2012;126:19-28. doi:10.1111/ane.12016
Hussein G, Troupin AS, Montouris G. Gabapentin interaction with felbamate. Neurology. 1996;47(4):1106-1106. doi:10.1212/WNL.47.4.1106
Yin J, Wang J. Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B. 2016;6(5):363-373. doi:10.1016/j.apsb.2016.07.013
Sánchez-Romero A, Durán-Quintana JA, García-Delgado R, et al. Possible gabapentin phenytoin interaction. Rev Neurol. 2002;34(10):952-953. doi:10.33588/rn.3410.2001491
Road traffic injuries [Internet]. [cited 2022 Apr 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/road-traffic-injuries
Konstantinides SV. Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us - and what they don't. Eur Respir J. 2021;58(1):2101111. doi:10.1183/13993003.01111-2021
Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22(6):bbab347. doi:10.1093/bib/bbab347
Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: Findings from the RANSOM Study. Neurology. 2008;71(20):1572-1578. doi:10.1212/01.wnl.0000319693.10338.b9
Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017;377(5):411-414. doi:10.1056/NEJMp1704633